The Complement System and Cancer Cachexia
补体系统和癌症恶病质
基本信息
- 批准号:10537488
- 负责人:
- 金额:$ 47.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenocarcinomaAffectAtrophicBody Weight decreasedC3AR1 geneCachexiaCalciumCancer PatientCell NucleusCellsChimeric ProteinsCollagenComplementComplement 3aComplement 3d ReceptorsComplement 5aComplement ActivationComplement InactivatorsComplement Membrane Attack ComplexDataDepositionDevelopmentDiseaseEventFatty acid glycerol estersFoundationsFunctional disorderGoalsHealthHomeostasisImmuneImpairmentInfiltrationInflammationInjectionsKPC modelKnock-outKnowledgeLeadLectinLeukocytesLinkLiverMalignant NeoplasmsMalignant neoplasm of pancreasMediatingModelingMusMuscleMuscle CellsMuscle FibersMuscle WeaknessMuscle functionMuscular AtrophyNatural regenerationNutritional SupportOpsoninPancreasPancreatic Ductal AdenocarcinomaPathologicPathologyPathway interactionsPatientsPersonsPharmacologyPhenotypePhysical FunctionProteinsProteomicsQuality of lifeRoleSiteSkeletal MuscleSourceStimulusSyndromeTestingTherapeuticTissuesTranscriptTranslatingTumor BurdenWorkbasecancer cachexiacancer surgerycancer survivalcancer therapycell typeclinically relevantcomplement pathwaycomplement systemconventional therapyimprovedinsightmortalitymouse modelmuscle formmuscle regenerationnovelpancreatic cancer modelpancreatic cancer patientspancreatic neoplasmpreservationpreventresponseskeletal muscle wastingtherapeutically effectivetherapy developmenttranscriptome sequencingtranslational potentialtreatment strategytumortumor progression
项目摘要
Project Summary/Abstract
Cachexia is characterized by progressive skeletal muscle and body weight loss and affects up to 80% of cancer
patients. Since this loss of muscle mass contributes to weakness, reduced tolerance to conventional treatments,
and increased mortality, understanding the mechanisms that drive muscle wasting is critical to the development
of treatments to improve quality of life and enhance survival of cancer patients. However, in exploring the
mechanisms that may drive cancer-induced atrophy of myofibers, it is important to do so in the context of the
broader muscle pathologies that we and others have shown in the muscle of cachectic tumor bearing hosts,
including tissue damage, non-resolute inflammation, impaired regeneration, and increased fat, collagen and
calcium deposition. Unpublished proteomics data from our lab collected in the skeletal muscle of cachectic
pancreatic cancer patients and, subsequently, cachectic mice bearing pancreatic tumors, releaved an
enrichment of multiple pathways of the complement (Cp) system. Further immunohistochemical analyses
revealed increased deposition of the central component of the Cp system, C3, and the terminal
pathway/membrane attack complex (MAC) within muscle tissues of people and mice with pancreatic tumors,
compared to controls. Based on these findings and the established roles of Cp proteins in causing inflammation
and tissue damage, we injected mouse pancreatic cancer (KPC) cells into the pancreas of C3 knockout (C3-/-)
mice and found significant protection against KPC-induced muscle wasting and weakness, that was further linked
to reduced leukocyte infiltration into muscle and reduced fibrotic remodeling. These overall findings establish the
requirement of Cp activation for the development of cachexia, with strong translational relevance. Aim 1 will
build on these foundational findings and identify the specific Cp activation pathway and effector mechanism(s)
required for the development of tumor-induced muscle pathologies and cachexia. This will reveal optimum points
in the Cp pathway for pharmacological blockade. Aim 2 will utilize mouse Cp inhibitors that function at different
points in the Cp pathway, targeted to sites of Cp deposition, to identify the most effective therapeutic strategy to
prevent and reverse cachexia in tumor bearing mice using both the KPC model and C26 adenocarcinoma model.
Aim 3 will determine the sufficiency and requirement of local myofiber-derived C3 in pancreatic cancer-induced
immune cell infiltration into muscle, muscle damage, atrophy and weakness. This mechanistic aim is important
because the role of local myofiber-derived Cp in muscle health and disease is almost completely unknown.
Therefore, our findings here will provide mechanistic insights that will enable us to optimize and develop novel
Cp inhibitory strategies for the treatment of a broad range of muscle conditions.
项目概要/摘要
恶病质的特点是进行性骨骼肌和体重减轻,影响高达 80% 的癌症
患者。由于肌肉质量的损失会导致虚弱,降低对传统治疗的耐受性,
和死亡率增加,了解导致肌肉萎缩的机制对于发展至关重要
改善生活质量并提高癌症患者生存率的治疗方法。然而,在探索
可能驱动癌症引起的肌纤维萎缩的机制,因此在以下背景下这样做很重要
我们和其他人在恶病质肿瘤宿主的肌肉中展示了更广泛的肌肉病理,
包括组织损伤、非彻底的炎症、再生受损以及脂肪、胶原蛋白和
钙沉积。我们实验室在恶病质骨骼肌中收集的未发表的蛋白质组学数据
胰腺癌患者以及随后携带胰腺肿瘤的恶病质小鼠,释放了
补体(Cp)系统多种途径的富集。进一步的免疫组织化学分析
揭示了 Cp 系统的中心成分 C3 和末端的沉积增加
患有胰腺肿瘤的人和小鼠的肌肉组织内的通路/膜攻击复合物(MAC),
与对照相比。基于这些发现以及 Cp 蛋白在引起炎症中的既定作用
和组织损伤,我们将小鼠胰腺癌(KPC)细胞注射到C3敲除(C3-/-)的胰腺中
小鼠,发现对 KPC 引起的肌肉萎缩和无力有显着的保护作用,这进一步相关
减少白细胞浸润到肌肉并减少纤维化重塑。这些总体发现确定了
Cp 激活是恶病质发生的必要条件,具有很强的转化相关性。目标1将
以这些基础发现为基础,确定特定的 Cp 激活途径和效应机制
肿瘤引起的肌肉病理学和恶病质的发展所必需的。这将揭示最佳点
在 Cp 途径中进行药理学阻断。目标 2 将利用小鼠 Cp 抑制剂,其作用于不同的
Cp 通路中的点,针对 Cp 沉积位点,以确定最有效的治疗策略
使用 KPC 模型和 C26 腺癌模型预防和逆转荷瘤小鼠的恶病质。
目标 3 将确定局部肌纤维衍生的 C3 在胰腺癌诱发中的充足性和需求
免疫细胞渗入肌肉,使肌肉受损、萎缩和无力。 This mechanistic aim is important
因为局部肌纤维衍生的 Cp 在肌肉健康和疾病中的作用几乎完全未知。
因此,我们的研究结果将提供机制见解,使我们能够优化和开发新颖的
用于治疗多种肌肉疾病的 Cp 抑制策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl Atkinson其他文献
Carl Atkinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl Atkinson', 18)}}的其他基金
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation
将免疫抑制剂靶向递送至移植物内皮以预防肺移植中的排斥反应
- 批准号:
10481101 - 财政年份:2022
- 资助金额:
$ 47.71万 - 项目类别:
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation
将免疫抑制剂靶向递送至移植物内皮以预防肺移植中的排斥反应
- 批准号:
10693272 - 财政年份:2022
- 资助金额:
$ 47.71万 - 项目类别:
Complement driven innate and adaptive autoreactivity in lung transplantation
肺移植中补体驱动的先天性和适应性自身反应
- 批准号:
10363208 - 财政年份:2021
- 资助金额:
$ 47.71万 - 项目类别:
Complement driven innate and adaptive autoreactivity in lung transplantation
肺移植中补体驱动的先天性和适应性自身反应
- 批准号:
10228849 - 财政年份:2020
- 资助金额:
$ 47.71万 - 项目类别:
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis
慢性鼻窦炎发病机制中上皮细胞补体的产生
- 批准号:
9886648 - 财政年份:2020
- 资助金额:
$ 47.71万 - 项目类别:
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery
脑死亡相关血管化复合同种异体移植物损伤及其对同种免疫和功能恢复的影响
- 批准号:
10293947 - 财政年份:2020
- 资助金额:
$ 47.71万 - 项目类别:
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis
慢性鼻窦炎发病机制中上皮细胞补体的产生
- 批准号:
10355859 - 财政年份:2020
- 资助金额:
$ 47.71万 - 项目类别:
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis
慢性鼻窦炎发病机制中上皮细胞补体的产生
- 批准号:
10094187 - 财政年份:2020
- 资助金额:
$ 47.71万 - 项目类别:
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery
脑死亡相关血管化复合同种异体移植物损伤及其对同种免疫和功能恢复的影响
- 批准号:
10399007 - 财政年份:2020
- 资助金额:
$ 47.71万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 47.71万 - 项目类别: